Cti biopharma 10k
WebMar 6, 2024 · You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this ... WebMar 1, 2024 · We opine that CTI BioPharma's current set-up represents an attractive risk-reward scenario with ~50% potential downside (around cash value of $1/share) and ~320% potential upside (bull case $7.6 ...
Cti biopharma 10k
Did you know?
WebAs of June 30, 2024 , the aggregate market value of the registrant’s common equity held by non-affiliates was approximately $252.1 million. Shares of common stock held by each e WebSEATTLE , Feb. 23, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its fourth quarter and full year 2024 financial results. Feb 07, 2024.
WebAnnual Report. If you would like to receive a printed copy of the current annual report, please call. 800.215.2355 or 206.272.4345, or complete our Information Request form. … WebCTI BioPharma Reports Fourth Quarter and Full Year 2024 Financial Results. Form 10-K. Q3. CTI BioPharma Reports Third Quarter 2024 Financial Results. Form 10-Q. Q2. CTI …
Web- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood … WebCTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio …
WebIn May 2014, we changed our name from “Cell Therapeutics, Inc.” to “CTI BioPharma Corp.” We completed our initial public offering in 1997 and our shares are listed on The …
WebSector Healthcare More. 201-500 Employees. Based in Seattle, Washington. CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel … eastman cabinsWebMar 31, 2024 · SEATTLE, March 31, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended … cultura red hot chili peppersWebMar 20, 2024 · CTI develops novel therapies for patients with rare blood-related cancers by uncovering the underlying scientific drivers of their disease. Learn More Approved in the U.S. for adults with myelofibrosis … culturatech agris supportWebApr 7, 2024 · CTI BioPharma Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. CTI BioPharma Corp’s trailing 12-month revenue is $53.9 million with a -172.4% profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.216 per share for the … eastman brake flaring toolWebAug 25, 2024 · Aug 25, 2024, 07:00 ET. SEATTLE and TORONTO, Aug. 25, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (DRI) today announced ... cultura sparkassentheater an der emsWebSep 21, 2024 · CTI BioPharma Investor Contacts: Argot Partners +212-600-1902 [email protected] SOURCE CTI BioPharma Corp. culturatech webexWebJul 18, 2024 · Shares of CTI BioPharma Corp. ( CTIC -0.38%) plunged 41.3% as of 11:24 a.m. EDT on Wednesday after the company provided an update from its meeting with the U.S. Food and Drug Administration (FDA ... culturatech webex.com